Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep Apnea

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

Also called NCT06690723

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 160 participants (enrolled count) (from the registry)
Sponsor
University Malaysia Sarawak (from the registry)
Registry
  • NCT NCT06690723
Other papers using this trial's data
  • Unveiling the benefits of Vitamin D3 with SGLT-2 inhibitors for hypertensive obese obstructive sleep apnea patients Journal of translational medicine, 2025-03-07 DOI, PubMed 40055713, PMC11889775 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Malaysia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06690723. Randomized; single masking; primary purpose treatment. Start 2022-06-08 (actual); primary completion 2024-09-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep Apnea
Acronym
D3DOSA
Condition
Obstructive Sleep Apnea
Intervention (Drug)
Dapagliflozin (Forxiga)
Intervention (Drug)
Vitamin D3 ( Colecalciferol)
Intervention (Drug)
Vitamin D3 plus Dapagliflozin
Intervention (Behavioral)
Lifestyle modification
Lead sponsor
University Malaysia Sarawak (class: other)

Record details

Record id
cardio:ct-nct06690723
Content hash
2b4c40748e821a202c512f000fc2c84389c2e54ef88dad6fd60258e03bd4a7c9